公开(公告)号：US12221426B2

公开(公告)日：2025-02-11

申请号：US17271354

申请日：2019-08-29

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  NATIONAL CANCER CENTER

Inventor： Bong-Jin Lee ,  Kyu-Yeon Lee ,  Sang Jae Lee ,  Dong-Gyun Kim ,  Joo Youn Lee ,  Kwan-Young Jeong ,  Heui Cherl Yang ,  Hyeon-Kyu Lee ,  Hyoun Sook Kim

IPC: C07D277/32 ,  A61P3/06 ,  A61P35/00 ,  A61K31/426

Abstract: A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.

公开(公告)号：US11192878B2

公开(公告)日：2021-12-07

申请号：US16609805

申请日：2018-05-11

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon Hwang ,  Jae Du Ha ,  Sung Yun Cho ,  Pil Ho Kim ,  Chang Soo Yun ,  Chi Hoon Park ,  Chong Ock Lee ,  Sang Un Choi ,  Joo Youn Lee ,  Sunjoo Ahn

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14

Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.

公开(公告)号：US10765669B2

公开(公告)日：2020-09-08

申请号：US16470014

申请日：2017-12-15

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Sungchan Cho ,  Miri Choi ,  Joo Youn Lee

IPC: A61K31/381 ,  A61K31/444 ,  A23L33/10

Abstract: The present invention relates to a pharmaceutical composition the prevention or treatment of DYRK-related diseases containing a pyridine-based compound as an active ingredient, a pyridine-based compound of the present invention which is used as an active ingredient of the pharmaceutical composition inhibits the activity of DYRK1A with very high efficacy and selectivity, thereby can be used effectively in the prevention or treatment of DYRK-related diseases, such as Down syndrome, degenerative brain diseases, cancer, and metabolic diseases.